Oliver Araújo Lacerda Cotta

Oliver Araújo Lacerda Cotta

Auto-generated profile, based on publicly available information

Oliver Araújo Lacerda Cotta

Research and Development, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
GFGustavo de Oliveira Fulgêncio
Gustavo de Oliveira Fulgêncio
LDLuisa Cangussú Domingos
Luisa Cangussú Domingos
OCOliver Araújo Lacerda Cotta
Oliver Araújo Lacerda Cotta
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

14 August 2020 in Planta Medica
Verified
Journal Article
Closed access
PDF file
LVLorena Carla Vieira
Lorena Carla Vieira
CMCarolina Paula de Souza Moreira
Carolina Paula de Souza Moreira
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
OCOliver Araújo Lacerda Cotta
Oliver Araújo Lacerda Cotta
LSLuciana Maria Silva
Luciana Maria Silva
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
Rosmarinic acid, a plant-derived compound with antiangiogenic activity, can be applied for the treatment of ocular diseases related to neovascularization, such as diabetic retinopathy, macular edema, and age-related macular degeneration. These diseases represent the leading causes of blindness worldwide if they are not properly treated. Intravitreal devices allow for localized drug delivery to the posterior segment, increasing the drug bioavailability and promoting extended release, thus, reducing side effects and enhancing the patientʼs compliance to the treatment. In this work, rosmarinic acid-loaded poly lactic-co-glycolic acid intraocular implants were developed with a view for the treatment of ocular neovascularization. Physical-chemical, biocompatibility, and safety studies of the implants were carried out in vitro and in vivo as well as an evaluation of the antiangiogenic activity in a chorioallantoic membrane assay. Data obtained showed that rosmarinic acid released from the implants was quantified in the vitreous for 6 weeks, while when it was in the solution formulation, after 24 h, no drug was found in the vitreous. The delivery device did not show any sign of toxicity after clinical evaluation and in electroretinographic findings. Histological analysis showed normal eye tissue. Rosmarinic acid released from implants reduced 30% of new vesselʼs formation. The intravitreal implant successfully allowed for the prolonged release of rosmarinic acid, was safe to rabbits eyes, and demonstrated activity in vessel reduction, thus demonstrating potential in preventing neovascularization in ophthalmic diseases.

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
LVLorena Carla Vieira
Lorena Carla Vieira
DVDaniel Vitor Vasconcelos-Santos
Daniel Vitor Vasconcelos-Santos
SCSarah Pereira de Freitas Cenachi
Sarah Pereira de Freitas Cenachi
OCOliver Araújo Lacerda Cotta
Oliver Araújo Lacerda Cotta
SFSílvia Ligório Fialho
Sílvia Ligório Fialho